Table 1 Clinical inputs (3-month probabilities) per therapy arm and severity state
From: Economic evaluation of trimetazidine in the management of chronic stable angina in Greece
Angina severity state at the end of the 3-month period | |||||
|---|---|---|---|---|---|
Angina severity state at baseline | Minimal | Mild | Moderate | Severe | Source |
TMZ 70 mg/d + SoC | |||||
Minimal | 94.66 % | 4.20 % | 1.15 % | 0.00 % | VASCO trial [25] |
Mild | 52.72 % | 41.30 % | 5.43 % | 0.54 % | |
Moderate | 19.42 % | 61.17 % | 15.53 % | 3.88 % | |
Severe | 14.29 % | 18.10 % | 24.76 % | 42.86 % | |
SoC | |||||
Minimal | 90.61 % | 9.39 % | 0.00 % | 0.00 % | |
Mild | 46.60 % | 41.88 % | 9.42 % | 2.09 % | |
Moderate | 25.84 % | 43.82 % | 23.60 % | 6.74 % | |
Severe | 11.72 % | 26.56 % | 15.63 % | 46.09 % | |